A Study to Compare the Pharmacokinetics and Safety of CT-P47 and RoActemra in Healthy Subjects

PHASE1UnknownINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

December 22, 2021

Primary Completion Date

October 1, 2022

Study Completion Date

January 31, 2023

Conditions

Healthy Subjects

Interventions

BIOLOGICAL

CT-P47

162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)

BIOLOGICAL

EU-approved RoActemra,

162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)

Trial Locations (1)

RECRUITING

Seoul National University Hospital, Seoul